Jordan R Hansford

List of Publications by Year
in descending order

117 papers	5,869 citations	159585 30 h-index	82547 72 g-index
123 all docs	123 docs citations	123 times ranked	8468 citing authors

#	Article	IF	Citations
1	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
2	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. Journal of Clinical Oncology, 2016, 34, 2206-2211.	1.6	692
3	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical Cancer Research, 2017, 23, e38-e45.	7.0	358
4	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	7.7	271
5	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nature Communications, 2019, 10, 4343.	12.8	200
6	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
7	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nature Medicine, 2020, 26, 1742-1753.	30.7	185
8	Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood. Clinical Cancer Research, 2017, 23, e32-e37.	7.0	157
9	Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutationâ€“Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clinical Cancer Research, 2019, 25, 7303-7311.	7.0	128
10	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	7.7	118
11	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835.	1.6	106
12	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell, 2020, 183, 1617-1633.e22.	28.9	93
13	Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. Clinical Cancer Research, 2017, 23, e107-e114.	7.0	91
14	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncology, 2022, 24, 997-1007.	1.2	72
15	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	16.8	69
16	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathologica, 2020, 139, 223-241.	7.7	65
17	Longâ€term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive. Cancer, 2015, 121, 4190-4196.	4.1	64
18	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell, 2021, 39, 1519-1530.e4.	16.8	64

#	Article	IF	Citations
19	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	3.0	62
20	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 2022, 28, 125-135.	30.7	53
21	Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. Journal of Neuro-Oncology, 2016, 128, 293-302.	2.9	51
22	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. Neuro-Oncology, 2020, 22, 1647-1657.	1.2	51
23	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro-Oncology, 2021, 23, 1360-1370.	1.2	46
24	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. Acta Neuropathologica, 2021, 141, 771-785.	7.7	44
25	Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive lowâ€grade glioma. Cancer Medicine, 2019, 8, 40-50.	2.8	41
26	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
27	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. Journal of Clinical Oncology, 2021, 39, 2779-2790.	1.6	40
28	Low rates of recurrence and slow progression of pediatric pilocytic astrocytoma after gross-total resection: justification for reducing surveillance imaging. Journal of Neurosurgery: Pediatrics, 2016, 17, 569-572.	1.3	38
29	Single agent carboplatin for pediatric lowâ€grade glioma: A retrospective analysis shows equivalent efficacy to multiagent chemotherapy. International Journal of Cancer, 2016, 138, 481-488.	5.1	36
30	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathologica, 2021, 142, 841-857.	7.7	36
31	Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600â€“mutant pediatric low-grade glioma (pLGG).. Journal of Clinical Oncology, 2022, 40, LBA2002-LBA2002.	1.6	35
32	Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in TP53-Associated Cancer Susceptibility. Journal of Clinical Oncology, 2016, 34, 3697-3704.	1.6	33
33	International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2019, 141, 253-263.	2.9	30
34	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. Neuro-Oncology, 2022, 24, 153-165.	1.2	28
35	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
36	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. Acta Neuropathologica, 2020, 140, 765-776.	7.7	23

#	Article	IF	Citations
37	Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. Journal of Neuro-Oncology, 2020, 147, 721-730.	2.9	21
38	â€œBalancing Expectations with Actual Realitiesâ€: Conversations with Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial. Journal of Personalized Medicine, 2020, 10, 9.	2.5	20
39	Carboplatin Hypersensitivity Reactions in Pediatric Low Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy. Pediatric Blood and Cancer, 2016, 63, 17-20.	1.5	19
40	Bevacizumab for NF2â€associated vestibular schwannomas of childhood and adolescence. Pediatric Blood and Cancer, 2020, 67, e28228.	1.5	17
41	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600â€“mutant relapsed refractory low-grade glioma.. Journal of Clinical Oncology, 2018, 36, 10506-10506.	1.6	17
42	Idiosyncratic nature of voriconazole photosensitivity in children undergoing cancer therapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 1807-1809.	3.0	15
43	Clinical Utility of Precision Medicine in Pediatric Oncology: A Systematic Review. JCO Precision Oncology, 2021, 5, 1088-1102.	3.0	14
44	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	5.6	12
45	A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy. Haematologica, 2014, 99, e156-e158.	3.5	9
46	Central Diabetes Insipidus and Cisplatin-Induced Renal Salt Wasting Syndrome: A Challenging Combination. Pediatric Blood and Cancer, 2016, 63, 925-927.	1.5	9
47	Bevacizumab for pediatric radiation necrosis. Neuro-Oncology Practice, 2020, 7, 409-414.	1.6	9
48	Characteristics of patients â‰¥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro-Oncology, 2022, 24, 141-152.	1.2	9
49	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. Neuro-Oncology, 2022, 24, 821-833.	1.2	9
50	Personalised medicine in paediatric oncology: Ethical practice outside the clinical trial framework?. Journal of Paediatrics and Child Health, 2019, 55, 10-12.	0.8	8
51	Cancer in <scp>A</scp>ustralian <scp>A</scp>boriginal children: Room for improvement. Journal of Paediatrics and Child Health, 2013, 49, 27-32.	0.8	7
52	In utero and early postnatal presentation of autoimmune lymphoproliferative syndrome in a family with a novel FAS mutation. Haematologica, 2013, 98, e38-e39.	3.5	7
53	Spinal Cord Hyperintensities in Neurofibromatosis Type 1: Are They the Cord Equivalent of Unidentified Bright Objects in the Brain?. Pediatric Neurology, 2018, 86, 63-65.	2.1	6
54	Pediatric Pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neuro-Oncology Advances, 0, , .	0.7	6

#	Article	IF	Citations
55	Efficacy of acute myeloid leukemia therapy without stem-cell transplantation in a child with blastic plasmacytoid dendritic cell neoplasm. Haematologica, 2013, 98, e30-e31.	3.5	5
56	Rare Embryonal Brain Tumours. , 2018, , 289-316.		5
57	Treatment response of CNS highâ€grade neuroepithelial tumors with MN1 alteration. Pediatric Blood and Cancer, 2020, 67, e28627.	1.5	5
58	Recurrent SPECC1Lâ€“NTRK fusions in pediatric sarcoma and brain tumors. Journal of Physical Education and Sports Management, 2020, 6, a005710.	1.2	4
59	Characteristics of children â‰36 months of age with DIPG: A report from the international DIPG registry. Neuro-Oncology, 2022, 24, 2190-2199.	1.2	4
60	FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS10062-TPS10062.	1.6	4
61	Report of a bi-allelic truncating germline mutation in TP53. Familial Cancer, 2019, 18, 101-104.	1.9	3
62	IMMU-08. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: efficacy, safety, biomarker, and pharmacokinetic results from Checkmate 908. Neuro-Oncology, 2022, 24, i82-i83.	1.2	3
63	Radiomics â€“ A new age of presurgical assessment to improve outcomes in pediatric neuro-oncology. Neuro-Oncology, 2022, , .	1.2	2
64	PNR-33MOLECULAR RE-EVALUATION OF INSTITUTIONALLY DIAGNOSED CNS-PNETS: CLINICAL CONSEQUENCES OF CONFINED DIAGNOSTIC GROUPS. Neuro-Oncology, 2016, 18, iii13.2-iii13.	1.2	1
65	PNR-05PRIMITIVE MYXOID MESENCHYMAL TUMOUR OF INFANCY â€“ A CASE OF EARLY CHEMOTHERAPY-RESPONSIVENESS AND REVIEW OF THE LITERATURE. Neuro-Oncology, 2016, 18, iii7.5-iii8.	1.2	1
66	PNR-40EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES: A UNIQUE NEW CLINICAL ENTITY. Neuro-Oncology, 2016, 18, iii15.2-iii15.	1.2	1
67	DIPG-69. CHARACTERISTICS OF PATIENTS â‰¥ 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2018, 20, i63-i63.	1.2	1
68	Malignant Melanoma in Children and Adolescents Treated in Pediatric Oncology Centers: An Australian and New Zealand Childrenâ€™s Oncology Group (ANZCHOG) Study. Frontiers in Oncology, 2021, 11, 660172.	2.8	1
69	An institutional audit of the use of novel drugs in pediatric oncology. Cancer Reports, 2021, , e1404.	1.4	1
70	MBRS-54. POOR SURVIVAL IN REPLICATION REPAIR DEFICIENT HYPERMUTANT MEDULLOBLASTOMA AND CNS EMBRYONAL TUMORS: A REPORT FROM THE INTERNATIONAL RRD CONSORTIUM. Neuro-Oncology, 2020, 22, iii407-iii407.	1.2	1
71	RARE-15. EARLY PSEUDOPROGRESSION POST-RADIATION IN PAEDIATRIC HIGH-GRADE GLIOMA PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY: TWO CASE REPORTS FROM A SINGLE CENTRE. Neuro-Oncology, 2020, 22, iii444-iii445.	1.2	1
72	CTNI-58. EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT AND PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. Neuro-Oncology, 2021, 23, vi73-vi74.	1.2	1

#	Article	IF	Citations
73	ATRT-17. A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumours and atypical teratoid rhabdoid tumours.. Neuro-Oncology, 2022, 24, i6-i7.	1.2	1
74	HG-53HYPERMUTATION AND NEOANTIGEN FORMATION PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN CHILDHOOD BIALLELIC MISMATCH REPAIR DEFICIENT GLIOBLASTOMA. Neuro-Oncology, 2016, 18, iii59.2-iii60.	1.2	0
75	LG-15RISK ASSESSMENT IN PAEDIATRIC GLIOMA - TIME TO MOVE ON FROM THE BINARY CLASSIFICATION. Neuro-Oncology, 2016, 18, iii81.4-iii81.	1.2	0
76	PDCT-09. HYPERMUTATION AND NEOANTIGEN FORMATION IS DIAGNOSTIC AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN CHILDHOOD BIALLELIC MISMATCH REPAIR DEFICIENT BRAIN TUMORS. Neuro-Oncology, 2016, 18, vi147-vi147.	1.2	0
77	Reply to Comment on: Carboplatin Hypersensitivity Reactions in Pediatric Low Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy. Pediatric Blood and Cancer, 2016, 63, 175-175.	1.5	0
78	PNR-39DISTINCT GENE FUSIONS SEGREGATE SUB-CLASSES OF CNS-PNETs. Neuro-Oncology, 2016, 18, iii15.1-iii15.	1.2	0
79	Sa2045 Tumor Spectrum, Diagnostic Tools and Survival in Patients With Biallelic Mismatch Repair Gene Deficiency (BMMRD) Syndrome: Report From the International BMMRD Consortium. Gastroenterology, 2016, 150, S438-S439.	1.3	0
80	GERM-23. INTRACRANIAL GROWING TERATOMA SYNDROME (IGTS): AN INTERNATIONAL RETROSPECTIVE STUDY. Neuro-Oncology, 2018, 20, i88-i88.	1.2	0
81	31 Intracranial growing teratoma syndrome (IGTS): An international retrospective study. Canadian Journal of Neurological Sciences, 2018, 45, S13-S13.	0.5	0
82	HGG-20. DNA METHYLATION ANALYSIS OF HIGH-GRADE GLIOMA IN PATIENTS WITH MISMATCH REPAIR DEFICIENCIES. Neuro-Oncology, 2018, 20, i92-i93.	1.2	0
83	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. Neuro-Oncology, 2018, 20, i117-i117.	1.2	0
84	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. Neuro-Oncology, 2018, 20, i72-i73.	1.2	0
85	DIPG-36. CLINICAL, RADIOLOGICAL, AND HISTO-MOLECULAR CHARACTERISTICS OF DIFFUSE INTRINSIC PONTINE GLIOMA IN PATIENTS WHO SURVIVE LESS THAN 3 MONTHS FROM DIAGNOSIS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2019, 21, ii76-ii77.	1.2	0
86	GENE-04. ESTABLISHING A MOLECULAR PROFILING SERVICE FOR CHILDRENâ€™S CENTRAL NERVOUS SYSTEM TUMORS IN AUSTRALASIA â€“ THE AUSTRALIAN AND NEW ZEALAND CHILDRENâ€™S HAEMATOLOGY AND ONCOLOGY GROUP (ANZCHOG) AIM BRAIN PROJECT. Neuro-Oncology, 2019, 21, ii81-ii81.	1.2	0
87	PDCT-08. SUPERIOR OUTCOME FOR BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. Neuro-Oncology, 2019, 21, vi184-vi185.	1.2	0
88	PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. Neuro-Oncology, 2019, 21, vi192-vi192.	1.2	0
89	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii102-ii102.	1.2	0
90	Preoperative chemotherapy in medulloblastoma: a change in treatment paradigm?. Neuro-Oncology, 2020, 22, 1562-1563.	1.2	0

#	Article	IF	Citations
91	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. Neuro-Oncology, 2020, 22, iii327-iii328.	1.2	0
92	Growth hormone and targeted oncological agents: Are we stopping children with brain tumours from reaching their true height potential?. Journal of Paediatrics and Child Health, 2021, 57, 1170-1174.	0.8	0
93	RARE-07. EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. Neuro-Oncology, 2021, 23, i42-i42.	1.2	0
94	An unexpected disease course for a patient with diffuse midline glioma. Pediatric Blood and Cancer, 2021, 68, e29205.	1.5	0
95	Abstract NG05: TP53-mediated human cancer susceptibility is defined by epigenetic dysregulation of microRNA-34A. , 2017, , .		0
96	Genomic landscape of pineoblastoma.. Journal of Clinical Oncology, 2018, 36, 2028-2028.	1.6	0
97	ATRT-08. A PHASE II STUDY OF CONTINUOUS LOW DOSE PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH MALIGNANT RHABDOID TUMORS/ATYPICAL TERATOID RHABDOID TUMORS. Neuro-Oncology, 2020, 22, iii277-iii277.	1.2	0
98	RARE-17. SURVIVAL BENEFIT FOR INDIVIDUALS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME AND BRAIN TUMORS WHO UNDERGO SURVEILLANCE PROTOCOL. A REPORT FROM THE INTERNATIONAL REPLICATION REPAIR CONSORTIUM. Neuro-Oncology, 2020, 22, iii445-iii446.	1.2	0
99	PATH-01. MOLECULAR PROFILING OF PAEDIATRIC CENTRAL NERVOUS SYSTEM TUMOURS IN AUSTRALASIA â€“ AN UPDATE ON THE AIM BRAIN AND MNP2.0 PROJECTS. Neuro-Oncology, 2020, 22, iii424-iii424.	1.2	0
100	EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDRENâ€™S HAEMATOLOGY/ONCOLOGY GROUP. Neuro-Oncology, 2020, 22, iii315-iii315.	1.2	0
101	DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2020, 22, iii301-iii302.	1.2	0
102	DIPG-55. PATTERNS OF CEREBROSPINAL FLUID DIVERSION AND SURVIVAL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2020, 22, iii297-iii298.	1.2	0
103	MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY. Neuro-Oncology, 2020, 22, iii394-iii394.	1.2	0
104	MBRS-20. CSF-DERIVED CIRCULATING TUMOR DNA AS A BIOMARKER FOR DISEASE PROGRESSION AND TUMOR EVOLUTION IN MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii401-iii402.	1.2	0
105	DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. Neuro-Oncology, 2020, 22, iii295-iii296.	1.2	0
106	PATH-09. SJMB12 CLINICAL TRIAL: DISCREPANCY BETWEEN LOCAL AND CENTRAL PATHOLOGY IN ASSESSING ANAPLASTIC MEDULLOBLASTOMA â€“ REPORT FROM A SINGLE SITE EXPERIENCE. Neuro-Oncology, 2020, 22, iii426-iii426.	1.2	0
107	RARE-50. TREATMENT RESPONSE OF CNS HIGH-GRADE NEUROEPITHELIAL TUMORS WITH MN1 ALTERATION. Neuro-Oncology, 2020, 22, iii453-iii453.	1.2	0
108	HGG-20. DIAGNOSTIC AND BIOLOGICAL ROLE OF METHYLATION PATTERNS IN REPLICATION REPAIR DEFICIENT HIGH GRADE GLIOMAS. Neuro-Oncology, 2020, 22, iii347-iii348.	1.2	0

#	Article	IF	Citations
109	MBRS-60. THE ACTIONABLE GENOMIC LANDSCAPE OF RELAPSED MEDULLOBLASTOMA IS DEFINED BY MAINTENANCE AND ACQUISITION OF DRIVER EVENTS. Neuro-Oncology, 2020, 22, iii408-iii408.	1.2	0
110	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. Neuro-Oncology, 2020, 22, iii377-iii377.	1.2	0
111	INNV-43. MORE THAN WHAT MEETS THE EYE: ETMR AN UNDER RECOGNISED ATYPICAL BRAINSTEM PRIMARY. A RARE BRAIN TUMOR CONSORTIUM (RBTC) STUDY. Neuro-Oncology, 2021, 23, vi114-vi115.	1.2	0
112	DIPG-25. Patterns of cerebrospinal fluid diversion and survival in children with diffuse intrinsic pontine glioma: a report from the International Diffuse Intrinsic Pontine Glioma Registry. Neuro-Oncology, 2022, 24, i23-i24.	1.2	0
113	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. Neuro-Oncology, 2022, 24, i61-i62.	1.2	0
114	LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology. Neuro-Oncology, 2022, 24, i101-i102.	1.2	0
115	MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?. Neuro-Oncology, 2022, 24, i117-i117.	1.2	0
116	Phase I results of the INFORM2 combination study of nivolumab and entinostat in children and adolescents: INFORM2 NivEnt.. Journal of Clinical Oncology, 2022, 40, 10034-10034.	1.6	0
117	Clinical characteristics and outcome of a large cohort of patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. Journal of Clinical Oncology, 2022, 40, 2052-2052.	1.6	0